HLA Typing for Transplant Market by Technology (PCR, NGS, Sanger), Product, Application, Type, End User - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key insights from primary experts
    • 2.1.2.4 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 MARKET ESTIMATION APPROACH
    • 2.2.1.1 Company revenue-based market estimation approach top-down approach
    • 2.2.1.2 Procedure-based market estimation bottom-up approach
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HLA TYPING FOR TRANSPLANT MARKET OVERVIEW
• 4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024
• 4.3 HLA TYPING FOR TRANSPLANT MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)
• 4.4 HLA TYPING FOR TRANSPLANT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising number of organ donors and transplant procedures
    • 5.2.1.2 Surge in organ failure cases due to increased prevalence of chronic diseases
    • 5.2.1.3 Increasing research activities and rising funding for organ transplantations
    • 5.2.1.4 Growing adoption of HLA typing in personalized medicines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of HLA typing products
    • 5.2.2.2 Shortage of healthy organs for transplants
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Adoption of NGS and automation for high-throughput needs
    • 5.2.3.2 Use of AI and ML in HLA typing for better accuracy and broader clinical utility
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory complexities across regions
    • 5.2.4.2 Lack of standardization across HLA typing laboratories
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY FRAMEWORK
    • 5.3.1.1 North America
      • 5.3.1.1.1 US
      • 5.3.1.1.2 Canada
    • 5.3.1.2 Europe
      • 5.3.1.2.1 UK
      • 5.3.1.2.2 France
      • 5.3.1.2.3 Germany
    • 5.3.1.3 Asia Pacific
      • 5.3.1.3.1 China
      • 5.3.1.3.2 Japan
      • 5.3.1.3.3 India
    • 5.3.1.4 Latin America
      • 5.3.1.4.1 Brazil
      • 5.3.1.4.2 Mexico
    • 5.3.1.5 Middle East & Africa
  • 5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESEARCH & DEVELOPMENT
  • 5.4.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT
  • 5.4.3 MARKETING, SALES, AND DISTRIBUTION, AND AFTERMARKET SERVICE
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.5.3 SALES & DISTRIBUTION AGENTS
  • 5.5.4 END USERS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO FOR HS CODE 3822, 2020-2024
  • 5.7.2 EXPORT SCENARIO FOR HS CODE 3822, 2020-2024
• 5.8 PATENT ANALYSIS
  • 5.8.1 LIST OF MAJOR PATENTS/PATENT APPLICATIONS
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023-2024
  • 5.9.2 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023-2024
  • 5.9.3 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022-2024
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Next-generation sequencing
    • 5.10.1.2 PCR-Sequence-specific oligonucleotide probes
  • 5.10.2 COMPLEMENTARY TECHNOLOGIES
    • 5.10.2.1 Single antigen-based assays
    • 5.10.2.2 Flow cytometry crossmatch
  • 5.10.3 ADJACENT TECHNOLOGIES
    • 5.10.3.1 Bioinformatics software
• 5.11 PORTER'S FIVE FORCE ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
  • 5.14.2 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
  • 5.14.3 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 UNMET NEEDS
• 5.18 IMPACT OF AI/GEN AI ON HLA TYPING FOR TRANSPLANT MARKET
  • 5.18.1 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE-TRANSPLANT EVALUATION
    • 5.18.1.1 AI use cases in HLA typing for transplant market
    • 5.18.1.2 Key companies implementing AI
  • 5.18.2 FUTURE OF AI IN HLA TYPING FOR TRANSPLANT MARKET
• 5.19 IMPACT OF 2025 US TARIFF ON HLA TYPING FOR TRANSPLANT MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 IMPACT ON COUNTRY/REGION
    • 5.19.4.1 North America
      • 5.19.4.1.1 US
    • 5.19.4.2 Europe
    • 5.19.4.3 Asia Pacific
  • 5.19.5 IMPACT ON END-USE INDUSTRIES

6 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & CONSUMABLES
  • 6.2.1 AVAILABILITY OF MULTIPLE VARIETIES OF REAGENTS & CONSUMABLES TO DRIVE ADOPTION IN HLA TYPING PHASES
• 6.3 INSTRUMENTS
  • 6.3.1 NEED FOR PRECISE AND RELIABLE HLA MATCHING IN BONE MARROW AND ORGAN TRANSPLANTS TO PROPEL MARKET GROWTH
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 GROWING AUTOMATION AND DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO AID MARKET GROWTH

7 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 MOLECULAR ASSAYS
  • 7.2.1 PCR-BASED MOLECULAR ASSAYS
    • 7.2.1.1 Sequence-specific primer-PCR
      • 7.2.1.1.1 Cost-effectiveness and high accuracy to drive identification of HLA variants at low to intermediate resolutions
    • 7.2.1.2 Sequence-specific oligonucleotide-PCR
      • 7.2.1.2.1 Development and commercialization of innovative sequence-specific oligonucleotide-PCR products to aid segment growth
    • 7.2.1.3 Real-time PCR
      • 7.2.1.3.1 High sensitivity, effective real-time DNA amplification monitoring, and minimal sample need to drive segment
    • 7.2.1.4 Other PCR-based molecular assays
• 7.3 SEQUENCING-BASED MOLECULAR ASSAYS
  • 7.3.1 SANGER SEQUENCING
    • 7.3.1.1 High accuracy and single-base resolution to detect allelic variants and confirm novel or rare alleles
  • 7.3.2 NEXT-GENERATION SEQUENCING
    • 7.3.2.1 Growing reliance on outsourcing in-house analysis to propel demand in tissue typing
  • 7.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
• 7.4 NON-MOLECULAR ASSAYS
  • 7.4.1 LOWER COSTS AND HIGHER SPECIFICITY TO DRIVE ADOPTION OVER MOLECULAR ASSAYS

8 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC APPLICATIONS
  • 8.2.1 ANTIBODY SCREENING
    • 8.2.1.1 Advancement in pre-transplant compatibility screening with NGS to aid segment growth
  • 8.2.2 CHIMERISM MONITORING
    • 8.2.2.1 Growing trend of personalized transplant medicine for effective post-procedural clinical risk management to fuel adoption
  • 8.2.3 OTHER DIAGNOSTIC APPLICATIONS
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS FOR TRANSPLANT DIAGNOSTICS RESEARCH TO FAVOR MARKET GROWTH

9 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE

• 9.1 INTRODUCTION
• 9.2 SOLID ORGAN TRANSPLANTS
  • 9.2.1 HIGH POPULARITY OF ORGAN DONATION AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
• 9.3 SOFT-TISSUE TRANSPLANTS
  • 9.3.1 NEED FOR HLA TYPING IN COMPOSITE TISSUE ALLOTRANSPLANTATION TO AID ADOPTION
• 9.4 STEM CELL TRANSPLANTS
  • 9.4.1 EXPANDING DIVERSITY OF DONOR REGISTRIES TO FUEL ADOPTION OF HLA TYPING

10 HLA TYPING FOR TRANSPLANT MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 INDEPENDENT REFERENCE LABORATORIES
  • 10.2.1 ADHERENCE TO QUALITY AND REGULATORY STANDARDS WITH HIGH-QUALITY SERVICES TO DRIVE MARKET GROWTH
• 10.3 HOSPITALS & TRANSPLANT CENTERS
  • 10.3.1 DEVELOPED HEALTHCARE INFRASTRUCTURE AND HIGH SUCCESS RATES IN TRANSPLANT PROCEDURES TO DRIVE MARKET
• 10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
  • 10.4.1 INCREASING COLLABORATIONS TO DEVELOP AND OPTIMIZE HLA TYPING FOR BETTER ACCURACY, SPECIFICITY, AND EFFICIENCY

11 HLA TYPING FOR TRANSPLANT MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate HLA typing for transplant market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Rising number of solid organ and hematopoietic stem cell transplants to drive market adoption of HLA typing
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High donor registration rates and favorable government initiatives to augment market growth
  • 11.3.3 UK
    • 11.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing adoption for donor-recipient compatibility testing to support market
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing popularity of solid organ donation to drive market
  • 11.3.6 ITALY
    • 11.3.6.1 Supportive government policies and strong healthcare infrastructure to spur market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Presence of leading global manufacturers of HLA typing products to drive market
  • 11.4.3 INDIA
    • 11.4.3.1 Rise in transplantation procedures and use of HLA typing for assessing donor-recipient compatibility to spur market growth
  • 11.4.4 JAPAN
    • 11.4.4.1 Increasing number of solid organ transplantation procedures and rising chronic diseases to favor market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing use of genomic testing and analysis and growing government backing for clinical diagnostics to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Government support and advanced healthcare to drive adoption of NGS HLA typing for better transplant outcomes
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growing elderly demographic and increasing funding from leading HLA typing manufacturers to propel market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Wide recipient base for organ transplant and rise in medical tourism to fuel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Improvements in healthcare infrastructure and focus on specialized medical services to augment market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Technology footprint
    • 12.5.5.5 Application footprint
    • 12.5.5.6 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 MAJOR PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services/Solutions offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ILLUMINA, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services/Solutions offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 QIAGEN
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services/Solutions offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 BIO-RAD LABORATORIES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services/Solutions offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services/Solutions offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 CAREDX, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services/Solutions offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches and approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 WERFEN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services/Solutions offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches
      • 13.1.7.3.2 Deals
  • 13.1.8 DIASORIN S.P.A.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services/Solutions offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product approvals
  • 13.1.9 TBG BIOTECHNOLOGY CORP.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services/Solutions offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 FUJIREBIO
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services/Solutions offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 BECTON, DICKINSON AND COMPANY
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services/Solutions offered
  • 13.1.12 EUROBIO SCIENTIFIC
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services/Solutions offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches and approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 PACBIO
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services/Solutions offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product approvals and updates
      • 13.1.13.3.2 Deals
  • 13.1.14 BAG DIAGNOSTICS GMBH
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services/Solutions offered
  • 13.1.15 CREATIVE BIOLABS
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services/Solutions offered
• 13.2 OTHER PLAYERS
  • 13.2.1 HISTOGENETICS LLC
  • 13.2.2 SCISCO GENETICS, INC.
  • 13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
  • 13.2.4 BIONOBIS
  • 13.2.5 TAKARA BIO INC.
  • 13.2.6 KRISHGEN BIOSYSTEMS
  • 13.2.7 SCIENCELL RESEARCH LABORATORIES, INC.
  • 13.2.8 PROIMMUNE LTD.
  • 13.2.9 ALPHA BIOTECH LIMITED
  • 13.2.10 BIOFORTUNA LIMITED

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 HLA TYPING FOR TRANSPLANT MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 HLA TYPING FOR TRANSPLANT MARKET ASSUMPTIONS
• TABLE 3 HLA TYPING FOR TRANSPLANT MARKET: RISK ANALYSIS
• TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 8 HLA TYPING MARKET: ROLE IN ECOSYSTEM
• TABLE 9 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020-2024 (USD THOUSAND)
• TABLE 10 HLA TYPING FOR TRANSPLANT MARKET: EXPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020-2024 (USD THOUSAND)
• TABLE 11 HLA TYPING FOR TRANSPLANT MARKET: LIST OF MAJOR PATENTS/ PATENT APPLICATIONS
• TABLE 12 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023-2024 (USD)
• TABLE 13 AVERAGE SELLING PRICING TREND OF INSTRUMENTS AND REAGENTS, BY REGION, 2022-2024 (USD THOUSAND)
• TABLE 14 HLA TYPING FOR TRANSPLANT MARKET: PORTERS FIVE FORCES
• TABLE 15 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
• TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR MAJOR END USERS
• TABLE 17 HLA TYPING FOR TRANSPLANT MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 18 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
• TABLE 19 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
• TABLE 20 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
• TABLE 21 HLA TYPING FOR TRANSPLANT MARKET: UNMET NEEDS
• TABLE 22 HLA TYPING FOR TRANSPLANT MARKET: KEY COMPANIES IMPLEMENTING AI
• TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 24 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 25 HLA TYPING FOR TRANSPLANT MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 26 HLA TYPING FOR TRANSPLANT MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 27 HLA TYPING FOR TRANSPLANT MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 29 HLA TYPING FOR TRANSPLANT TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 30 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 31 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 32 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 33 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 34 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 35 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 36 REAL-TIME PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 37 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 38 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 39 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 40 SANGER SEQUENCING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 41 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 42 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 43 HLA TYPING FOR TRANSPLANT MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 44 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 45 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 46 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 47 ANTIBODY SCREENING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 48 CHIMERISM MONITORING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 49 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 50 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 51 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2023-2030 (USD MILLION)
• TABLE 52 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 53 HLA TYPING FOR SOFT-TISSUE TRANSPLANTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 54 HLA TYPING FOR STEM CELL TRANSPLANTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 55 HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 56 HLA TYPING FOR TRANSPLANT MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2023-2030 (USD MILLION)
• TABLE 57 HLA TYPING FOR TRANSPLANT MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2023-2030 (USD MILLION)
• TABLE 58 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2023-2030 (USD MILLION)
• TABLE 59 HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 60 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE, 2023 (NUMBER OF TRANSPLANTS)
• TABLE 61 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 62 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 64 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 65 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 66 US: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 67 US: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 68 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 69 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 70 CANADA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 71 CANADA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 72 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 73 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 74 EUROPE: KEY MACROINDICATORS
• TABLE 75 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 77 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 78 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 79 GERMANY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 80 GERMANY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 81 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 82 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 83 UK: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 84 UK: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 85 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 86 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 87 FRANCE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 88 FRANCE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 89 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 90 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 91 SPAIN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 92 SPAIN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 93 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 94 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 95 ITALY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 96 ITALY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 97 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 98 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 99 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 100 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 101 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 102 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 103 ASIA PACIFIC: KEY MACROINDICATORS
• TABLE 104 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 106 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 107 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 108 CHINA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 109 CHINA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 110 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 111 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 112 INDIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 113 INDIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 114 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 115 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 116 JAPAN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 117 JAPAN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 118 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 119 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 120 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 121 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 122 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 123 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 124 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 125 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 126 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 127 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 128 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 129 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 130 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 131 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 132 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 133 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 135 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 136 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 137 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 138 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 139 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 140 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 141 MEXICO: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 142 MEXICO: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 143 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 144 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 145 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 146 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 147 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 148 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 149 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
• TABLE 150 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 151 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 152 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 153 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 154 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 155 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 156 GCC COUNTRIES: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 157 GCC COUNTRIES: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 158 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 159 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 160 REST OF MIDDLE EAST & AFRICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 161 REST OF MIDDLE EAST & AFRICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 162 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN HLA TYPING FOR TRANSPLANT MARKET
• TABLE 163 HLA TYPING FOR TRANSPLANT MARKET: DEGREE OF COMPETITION
• TABLE 164 HLA TYPING FOR TRANSPLANT MARKET: REGION FOOTPRINT
• TABLE 165 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 166 HLA TYPING FOR TRANSPLANT MARKET: TECHNOLOGY FOOTPRINT
• TABLE 167 HLA TYPING FOR TRANSPLANT MARKET: APPLICATION FOOTPRINT
• TABLE 168 HLA TYPING FOR TRANSPLANT MARKET: END-USER FOOTPRINT
• TABLE 169 HLA TYPING FOR TRANSPLANT MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
• TABLE 170 HLA TYPING FOR TRANSPLANT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION
• TABLE 171 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 172 HLA TYPING FOR TRANSPLANT MARKET: DEALS, JANUARY 2022-APRIL 2025
• TABLE 173 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 174 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 175 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 176 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 177 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 178 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 179 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 180 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 181 QIAGEN: COMPANY OVERVIEW
• TABLE 182 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 183 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 184 QIAGEN: DEALS, JANUARY 2022-APRIL 2025
• TABLE 185 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 186 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 187 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 188 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 189 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 190 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 191 CAREDX, INC.: COMPANY OVERVIEW
• TABLE 192 CAREDX, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 193 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 194 CAREDX, INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 195 WERFEN: COMPANY OVERVIEW
• TABLE 196 WERFEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 197 WERFEN: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 198 WERFEN: DEALS, JANUARY 2022-APRIL 2025
• TABLE 199 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 200 DIASORIN S.P.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 201 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 202 TBG BIOTECHNOLOGY CORP.: COMPANY OVERVIEW
• TABLE 203 TBG BIOTECHNOLOGY CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 204 TBG BIOTECHNOLOGY CORP.: PRODUCT APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 205 TBG BIOTECHNOLOGY CORP.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 206 FUJIREBIO: COMPANY OVERVIEW
• TABLE 207 FUJIREBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 208 FUJIREBIO: DEALS, JANUARY 2022-APRIL 2025
• TABLE 209 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
• TABLE 210 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 211 EUROBIO SCIENTIFIC: COMPANY OVERVIEW
• TABLE 212 EUROBIO SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 213 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 214 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022-APRIL 2025
• TABLE 215 PACBIO: COMPANY OVERVIEW
• TABLE 216 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 217 PACBIO: PRODUCT APPROVALS AND UPDATES, JANUARY 2022-APRIL 2025
• TABLE 218 PACBIO: DEALS, JANUARY 2022-APRIL 2025
• TABLE 219 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
• TABLE 220 BAG DIAGNOSTICS GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 221 CREATIVE BIOLABS: COMPANY OVERVIEW
• TABLE 222 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 223 HISTOGENETICS LLC: COMPANY OVERVIEW
• TABLE 224 SCISCO GENETICS, INC.: COMPANY OVERVIEW
• TABLE 225 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW
• TABLE 226 BIONOBIS: COMPANY OVERVIEW
• TABLE 227 TAKARA BIO INC.: COMPANY OVERVIEW
• TABLE 228 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW
• TABLE 229 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 230 PROIMMUNE LTD.: COMPANY OVERVIEW
• TABLE 231 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW
• TABLE 232 BIOFORTUNA LIMITED: COMPANY OVERVIEW

List of Figures

• FIGURE 1 HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 HLA TYPING FOR TRANSPLANT MARKET: YEARS CONSIDERED
• FIGURE 3 HLA TYPING FOR TRANSPLANT MARKET: RESEARCH DESIGN
• FIGURE 4 HLA TYPING FOR TRANSPLANT MARKET: KEY PRIMARY SOURCES
• FIGURE 5 HLA TYPING FOR TRANSPLANT MARKET: KEY INSIGHTS FROM PRIMARIES
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
• FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 8 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
• FIGURE 9 MARKET SIZE ESTIMATION FOR HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE ESTIMATION
• FIGURE 10 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2024)
• FIGURE 11 HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE- AND PROCEDURE-BASED MARKET ESTIMATION APPROACH
• FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 13 HLA TYPING FOR TRANSPLANT MARKET: DATA TRIANGULATION
• FIGURE 14 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 HLA TYPING FOR TRANSPLANT MARKET: REGIONAL SNAPSHOT
• FIGURE 18 IMPROVED HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
• FIGURE 19 US AND REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
• FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
• FIGURE 21 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
• FIGURE 22 HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 23 HLA TYPING FOR TRANSPLANT MARKET: VALUE CHAIN ANALYSIS
• FIGURE 24 HLA TYPING FOR TRANSPLANT MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 25 HLA TYPING FOR TRANSPLANT MARKET: ECOSYSTEM ANALYSIS
• FIGURE 26 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822 (2020-2024)
• FIGURE 27 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822 (2020-2024)
• FIGURE 28 HLA TYPING FOR TRANSPLANT MARKET: TOP PATENT APPLICANTS/ OWNERS (JANUARY 2014-DECEMBER 2025)
• FIGURE 29 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023-2024 (USD THOUSAND)
• FIGURE 30 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022-2024 (USD THOUSAND)
• FIGURE 31 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY REGION, 2022-2024 (USD THOUSAND)
• FIGURE 32 HLA TYPING FOR TRANSPLANT MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
• FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS
• FIGURE 35 HLA TYPING FOR TRANSPLANT MARKET: TRENDS/DISRUPTIONS I MPACTING CUSTOMERS' BUSINESSES
• FIGURE 36 HLA TYPING FOR TRANSPLANT MARKET: FUNDING AND NUMBER OF DEALS, 2019-2023
• FIGURE 37 HLA TYPING FOR TRANSPLANT MARKET: NUMBER OF DEALS, BY KEY PLAYER, 2019-2023
• FIGURE 38 HLA TYPING FOR TRANSPLANT MARKET: VALUE OF DEALS, BY KEY PLAYER, 2019-2023 (USD)
• FIGURE 39 AI USE CASES IN HLA TYPING FOR TRANSPLANT MARKET
• FIGURE 40 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
• FIGURE 41 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
• FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET (2020-2024)
• FIGURE 43 MARKET SHARE ANALYSIS OF PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET (2024)
• FIGURE 44 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 45 HLA TYPING FOR TRANSPLANT MARKET: COMPANY FOOTPRINT
• FIGURE 46 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 47 EV/EBITDA OF KEY VENDORS
• FIGURE 48 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 49 HLA TYPING FOR TRANSPLANT MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
• FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT
• FIGURE 52 QIAGEN: COMPANY SNAPSHOT
• FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
• FIGURE 54 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• FIGURE 55 CAREDX, INC.: COMPANY SNAPSHOT
• FIGURE 56 DIASORIN S.P.A.: COMPANY SNAPSHOT
• FIGURE 57 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
• FIGURE 58 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT
• FIGURE 59 PACBIO: COMPANY SNAPSHOT